Monitoring drug Efficacy through Multi-Omics Research initiative in Alzheimer’s Disease (MEMORI-AD): A protocol for a multisite exploratory prospective cohort study on the drug response-related clinical, genetic, microbial and metabolomic signatures in Filipino patients with Alzheimer’s disease
Introduction Dementia is one of the leading causes of disability among older people aged 60 years and above, with majority eventually being diagnosed with Alzheimer’s disease (AD). Pharmacological agents approved for dementia include acetylcholinesterase enzyme (AChE) inhibitors like rivastigmine, d...
Saved in:
| Main Authors: | Veeda Michelle M Anlacan, Fresthel Monica M Climacosa, Francis James A Gordovez, John Carlo B. Reyes, Ian Kim B Tabios, Rafael Vincent M Manalo, Joana Marie Ceripulo Cruz, Joannes Luke B Asis, Rozel B Razal, Mark Joseph M Abaca, Aira B Dacasin, Ayra Patrice N Espiritu, Nicole Clarence Louise L Gapaz, Melody Hope L Lee Yu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/11/e078660.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alzheimer's disease drug development pipeline: 2025
by: Jeffrey L. Cummings, et al.
Published: (2025-04-01) -
The safety profile of drug treatment of alzheimer's disease
by: V. А. Moroz
Published: (2013-06-01) -
Alzheimer's disease drug development pipeline: 2019
by: Jeffrey Cummings, et al.
Published: (2019-01-01) -
The Philippine COVID-19 Outcomes: a Retrospective study Of Neurological manifestations and Associated symptoms (The Philippine CORONA study): a protocol study
by: Adrian I Espiritu, et al.
Published: (2020-11-01) -
From genes to drugs: targeting Alzheimer’s with circadian insights
by: Zekun Li, et al.
Published: (2025-03-01)